Long-term efficacy and therapeutic drug monitoring of sertraline in major depression

Massimo C. Mauri, Alessio Fiorentini, Giancarlo Cerveri, Lucia S. Volonteri, Francesca Regispani, Lara Malvini, Luigi Boscati, Rosa Lo Baido, Giordano Invernizzi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression. Twenty-three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM-IV criteria) were included. The patients were prescribed 25-150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS-A) and Hamilton rating scale for depression (HRS-D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25-50 ng/ml, were adequate for clinical maintenance treatment. Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment.

Original languageEnglish
Pages (from-to)385-388
Number of pages4
JournalHuman Psychopharmacology
Volume18
Issue number5
DOIs
Publication statusPublished - Jul 2003

Fingerprint

Sertraline
Drug Monitoring
Depression
Brief Psychiatric Rating Scale
Major Depressive Disorder
Therapeutics
Disease Management
Diagnostic and Statistical Manual of Mental Disorders
Chronic Disease
Outpatients
Anxiety
Recurrence
Pharmaceutical Preparations

Keywords

  • Long term efficacy
  • Major depression
  • Plasma levels
  • Prophylaxis
  • Sertraline

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. / Mauri, Massimo C.; Fiorentini, Alessio; Cerveri, Giancarlo; Volonteri, Lucia S.; Regispani, Francesca; Malvini, Lara; Boscati, Luigi; Lo Baido, Rosa; Invernizzi, Giordano.

In: Human Psychopharmacology, Vol. 18, No. 5, 07.2003, p. 385-388.

Research output: Contribution to journalArticle

Mauri, MC, Fiorentini, A, Cerveri, G, Volonteri, LS, Regispani, F, Malvini, L, Boscati, L, Lo Baido, R & Invernizzi, G 2003, 'Long-term efficacy and therapeutic drug monitoring of sertraline in major depression', Human Psychopharmacology, vol. 18, no. 5, pp. 385-388. https://doi.org/10.1002/hup.502
Mauri, Massimo C. ; Fiorentini, Alessio ; Cerveri, Giancarlo ; Volonteri, Lucia S. ; Regispani, Francesca ; Malvini, Lara ; Boscati, Luigi ; Lo Baido, Rosa ; Invernizzi, Giordano. / Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. In: Human Psychopharmacology. 2003 ; Vol. 18, No. 5. pp. 385-388.
@article{0f04ffae4cba45e9955b30dea3db0bc6,
title = "Long-term efficacy and therapeutic drug monitoring of sertraline in major depression",
abstract = "Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression. Twenty-three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM-IV criteria) were included. The patients were prescribed 25-150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS-A) and Hamilton rating scale for depression (HRS-D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25-50 ng/ml, were adequate for clinical maintenance treatment. Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment.",
keywords = "Long term efficacy, Major depression, Plasma levels, Prophylaxis, Sertraline",
author = "Mauri, {Massimo C.} and Alessio Fiorentini and Giancarlo Cerveri and Volonteri, {Lucia S.} and Francesca Regispani and Lara Malvini and Luigi Boscati and {Lo Baido}, Rosa and Giordano Invernizzi",
year = "2003",
month = "7",
doi = "10.1002/hup.502",
language = "English",
volume = "18",
pages = "385--388",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Long-term efficacy and therapeutic drug monitoring of sertraline in major depression

AU - Mauri, Massimo C.

AU - Fiorentini, Alessio

AU - Cerveri, Giancarlo

AU - Volonteri, Lucia S.

AU - Regispani, Francesca

AU - Malvini, Lara

AU - Boscati, Luigi

AU - Lo Baido, Rosa

AU - Invernizzi, Giordano

PY - 2003/7

Y1 - 2003/7

N2 - Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression. Twenty-three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM-IV criteria) were included. The patients were prescribed 25-150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS-A) and Hamilton rating scale for depression (HRS-D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25-50 ng/ml, were adequate for clinical maintenance treatment. Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment.

AB - Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression. Twenty-three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM-IV criteria) were included. The patients were prescribed 25-150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS-A) and Hamilton rating scale for depression (HRS-D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25-50 ng/ml, were adequate for clinical maintenance treatment. Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment.

KW - Long term efficacy

KW - Major depression

KW - Plasma levels

KW - Prophylaxis

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=0041310983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041310983&partnerID=8YFLogxK

U2 - 10.1002/hup.502

DO - 10.1002/hup.502

M3 - Article

C2 - 12858326

AN - SCOPUS:0041310983

VL - 18

SP - 385

EP - 388

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 5

ER -